Donate

Publication Details

Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm
Palbociclib (Ibrance ®) (Polish)

Palbociclib (Ibrance ®) (Polish) (June 2018)

Palbociclib (Ibrance®) is a targeted therapy drug used to treat breast cancer that is oestrogen receptor positive and HER 2 negative. This factsheet describes what it is, how it is given, and possible side effects. 

Author(s)
Macmillan Cancer Support
Place of publication
London
Publisher
Macmillan Cancer Support
Date of publication
June 2018
Pages
7pp
Supplier
https://www.macmillan.org.uk/, https://be.macmillan.org.uk/be
Subject(s)
Breast cancer, Biological therapies, Targeted therapies
Format
Factsheet
Language
Polish
Download this resource
Download this resource
Back to results
Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm
Donate

About this site

Macmillan sites

Right there with you

We're here to provide physical, financial and emotional support. So whatever cancer throws your way, we're right there with you. Contact us

Follow us

© Macmillan Cancer Support 2019 © Macmillan Cancer Support, registered charity in England and Wales (261017), Scotland (SC039907) and the Isle of Man (604). Also operating in Northern Ireland. A company limited by guarantee, registered in England and Wales company number 2400969. Isle of Man company number 4694F. Registered office: 89 Albert Embankment, London SE1 7UQ. VAT no: 668265007